Annual report

Period2023-01-21 → 2024-01-20

Filed2024-04-17

StandardJapan GAAP

ConsolidatedYes

Data checks24 of 24 passed

Key figures · 148

Metric	Value	Period	Scope	Source row
Revenue	¥213.4bn	2023-01-21 → 2024-01-20	Cons.	Net sales
Revenue	¥160.1bn	2022-01-21 → 2023-01-20	Cons.	Net sales
Revenue	¥162.6bn	2021-01-21 → 2022-01-20^d	Cons.	Net sales (5-year summary)
Revenue	¥158.2bn	2020-01-21 → 2021-01-20^d	Cons.	Net sales (5-year summary)
Revenue	¥168.3bn	2019-01-21 → 2020-01-20^d	Cons.	Net sales (5-year summary)
Operating income	¥3.7bn	2023-01-21 → 2024-01-20	Cons.	Operating income
Operating income	¥707m	2022-01-21 → 2023-01-20	Cons.	Operating income
Ordinary income	¥3.1bn	2023-01-21 → 2024-01-20	Cons.	Ordinary income
Ordinary income	¥591m	2022-01-21 → 2023-01-20	Cons.	Ordinary income
Ordinary income	¥5.7bn	2021-01-21 → 2022-01-20^d	Cons.	Ordinary income loss (5-year summary)
Ordinary income	¥5.7bn	2020-01-21 → 2021-01-20^d	Cons.	Ordinary income loss (5-year summary)
Ordinary income	¥2.9bn	2019-01-21 → 2020-01-20^d	Cons.	Ordinary income loss (5-year summary)
Profit before tax	¥5.6bn	2023-01-21 → 2024-01-20	Cons.	Income before income taxes
Profit before tax	¥1.1bn	2022-01-21 → 2023-01-20	Cons.	Income before income taxes
Net income (owners)	¥4.4bn	2023-01-21 → 2024-01-20	Cons.	Profit loss attributable to owners of parent
Net income (owners)	−¥507m	2022-01-21 → 2023-01-20	Cons.	Profit loss attributable to owners of parent
Net income (owners)	¥4.0bn	2021-01-21 → 2022-01-20^d	Cons.	Profit loss attributable to owners of parent (5-year summary)
Net income (owners)	¥3.2bn	2020-01-21 → 2021-01-20^d	Cons.	Profit loss attributable to owners of parent (5-year summary)
Net income (owners)	¥1.8bn	2019-01-21 → 2020-01-20^d	Cons.	Profit loss attributable to owners of parent (5-year summary)
Net income	¥4.6bn	2023-01-21 → 2024-01-20	Cons.	Profit loss
Net income	−¥490m	2022-01-21 → 2023-01-20	Cons.	Profit loss
Total assets	¥177.6bn	at 2024-01-20	Cons.	Assets
Total assets	¥164.2bn	at 2023-01-20	Cons.	Assets
Total assets	¥159.0bn	at 2022-01-20^d	Cons.	Total assets (5-year summary)
Total assets	¥157.6bn	at 2021-01-20^d	Cons.	Total assets (5-year summary)
Total assets	¥163.4bn	at 2020-01-20^d	Cons.	Total assets (5-year summary)
Total liabilities	¥86.1bn	at 2024-01-20	Cons.	Liabilities
Total liabilities	¥80.1bn	at 2023-01-20	Cons.	Liabilities
Net assets / equity	¥91.5bn	at 2024-01-20	Cons.	Net assets
Net assets / equity	¥84.1bn	at 2023-01-20	Cons.	Net assets
Net assets / equity	¥83.3bn	at 2022-01-20^d	Cons.	Net assets
Net assets / equity	¥82.6bn	at 2021-01-20^d	Cons.	Net assets (5-year summary)
Net assets / equity	¥89.2bn	at 2020-01-20^d	Cons.	Net assets (5-year summary)
Cash and deposits	¥32.4bn	at 2024-01-20	Cons.	Cash and deposits
Cash and deposits	¥27.2bn	at 2023-01-20	Cons.	Cash and deposits
Cash & equivalents	¥33.7bn	at 2024-01-20	Cons.	Cash and cash equivalents
Cash & equivalents	¥29.2bn	at 2023-01-20	Cons.	Cash and cash equivalents
Cash & equivalents	¥30.1bn	at 2022-01-20^d	Cons.	Cash and cash equivalents
Cash & equivalents	¥32.7bn	at 2021-01-20^d	Cons.	Cash and cash equivalents (5-year summary)
Cash & equivalents	¥30.3bn	at 2020-01-20^d	Cons.	Cash and cash equivalents (5-year summary)
Operating cash flow	¥9.2bn	2023-01-21 → 2024-01-20	Cons.	Net cash provided by used in operating activities
Operating cash flow	¥5.1bn	2022-01-21 → 2023-01-20	Cons.	Net cash provided by used in operating activities
Operating cash flow	¥8.1bn	2021-01-21 → 2022-01-20^d	Cons.	Net cash provided by used in operating activities (5-year summary)
Operating cash flow	¥12.5bn	2020-01-21 → 2021-01-20^d	Cons.	Net cash provided by used in operating activities (5-year summary)
Operating cash flow	¥11.5bn	2019-01-21 → 2020-01-20^d	Cons.	Net cash provided by used in operating activities (5-year summary)
Investing cash flow	−¥1.2bn	2023-01-21 → 2024-01-20	Cons.	Net cash provided by used in investment activities
Investing cash flow	−¥5.0bn	2022-01-21 → 2023-01-20	Cons.	Net cash provided by used in investment activities
Investing cash flow	−¥6.5bn	2021-01-21 → 2022-01-20^d	Cons.	Net cash provided by used in investing activities (5-year summary)
Investing cash flow	−¥7.6bn	2020-01-21 → 2021-01-20^d	Cons.	Net cash provided by used in investing activities (5-year summary)
Investing cash flow	−¥15.5bn	2019-01-21 → 2020-01-20^d	Cons.	Net cash provided by used in investing activities (5-year summary)
Financing cash flow	−¥3.2bn	2023-01-21 → 2024-01-20	Cons.	Net cash provided by used in financing activities
Financing cash flow	−¥1.1bn	2022-01-21 → 2023-01-20	Cons.	Net cash provided by used in financing activities
Financing cash flow	−¥3.7bn	2021-01-21 → 2022-01-20^d	Cons.	Net cash provided by used in financing activities (5-year summary)
Financing cash flow	−¥2.3bn	2020-01-21 → 2021-01-20^d	Cons.	Net cash provided by used in financing activities (5-year summary)
Financing cash flow	−¥4.1bn	2019-01-21 → 2020-01-20^d	Cons.	Net cash provided by used in financing activities (5-year summary)
EPS (basic)	¥140.77	2023-01-21 → 2024-01-20	Cons.	Basic earnings loss per share (5-year summary)
EPS (basic)	¥-16.2	2022-01-21 → 2023-01-20	Cons.	Basic earnings loss per share (5-year summary)
EPS (basic)	¥127.1	2021-01-21 → 2022-01-20^d	Cons.	Basic earnings loss per share (5-year summary)
EPS (basic)	¥100.66	2020-01-21 → 2021-01-20^d	Cons.	Basic earnings loss per share (5-year summary)
EPS (basic)	¥54	2019-01-21 → 2020-01-20^d	Cons.	Basic earnings loss per share (5-year summary)
Net assets per share	¥2,843.99	at 2024-01-20	Cons.	Net assets per share (5-year summary)
Net assets per share	¥2,663.79	at 2023-01-20	Cons.	Net assets per share (5-year summary)
Net assets per share	¥2,645.36	at 2022-01-20^d	Cons.	Net assets per share (5-year summary)
Net assets per share	¥2,612.23	at 2021-01-20^d	Cons.	Net assets per share (5-year summary)
Net assets per share	¥2,670.68	at 2020-01-20^d	Cons.	Net assets per share (5-year summary)
Equity ratio	50.4%	at 2024-01-20	Cons.	Equity to asset ratio (5-year summary)
Equity ratio	50.9%	at 2023-01-20	Cons.	Equity to asset ratio (5-year summary)
Equity ratio	52.1%	at 2022-01-20^d	Cons.	Equity to asset ratio (5-year summary)
Equity ratio	51.8%	at 2021-01-20^d	Cons.	Equity to asset ratio (5-year summary)
Equity ratio	53.9%	at 2020-01-20^d	Cons.	Equity to asset ratio (5-year summary)
ROE	5.1%	2023-01-21 → 2024-01-20	Cons.	Rate of return on equity (5-year summary)
ROE	-0.6%	2022-01-21 → 2023-01-20	Cons.	Rate of return on equity (5-year summary)
ROE	4.8%	2021-01-21 → 2022-01-20^d	Cons.	Rate of return on equity (5-year summary)
ROE	3.8%	2020-01-21 → 2021-01-20^d	Cons.	Rate of return on equity (5-year summary)
ROE	2.0%	2019-01-21 → 2020-01-20^d	Cons.	Rate of return on equity (5-year summary)
Employees	5,182	at 2024-01-20	Cons.	Number of employees
Employees	4,122	at 2023-01-20	Cons.	Number of employees
Employees	4,029	at 2022-01-20^d	Cons.	Number of employees
Employees	3,922	at 2021-01-20^d	Cons.	Number of employees
Employees	4,160	at 2020-01-20^d	Cons.	Number of employees
Revenue	¥5.3bn	2023-01-21 → 2024-01-20	Standalone	Operating revenue1
Revenue	¥5.0bn	2022-01-21 → 2023-01-20	Standalone	Operating revenue1
Revenue	¥4.8bn	2021-01-21 → 2022-01-20^d	Standalone	Operating revenue1 (5-year summary)
Revenue	¥4.8bn	2020-01-21 → 2021-01-20^d	Standalone	Operating revenue1 (5-year summary)
Revenue	¥6.6bn	2019-01-21 → 2020-01-20^d	Standalone	Operating revenue1 (5-year summary)
Operating income	¥1.1bn	2023-01-21 → 2024-01-20	Standalone	Operating income
Operating income	¥1.7bn	2022-01-21 → 2023-01-20	Standalone	Operating income
Ordinary income	¥2.0bn	2023-01-21 → 2024-01-20	Standalone	Ordinary income
Ordinary income	¥2.3bn	2022-01-21 → 2023-01-20	Standalone	Ordinary income
Ordinary income	¥2.4bn	2021-01-21 → 2022-01-20^d	Standalone	Ordinary income loss (5-year summary)
Ordinary income	¥1.9bn	2020-01-21 → 2021-01-20^d	Standalone	Ordinary income loss (5-year summary)
Ordinary income	¥4.0bn	2019-01-21 → 2020-01-20^d	Standalone	Ordinary income loss (5-year summary)
Profit before tax	¥4.0bn	2023-01-21 → 2024-01-20	Standalone	Income before income taxes
Profit before tax	¥2.8bn	2022-01-21 → 2023-01-20	Standalone	Income before income taxes
Net income	¥2.9bn	2023-01-21 → 2024-01-20	Standalone	Profit loss
Net income	¥1.9bn	2022-01-21 → 2023-01-20	Standalone	Profit loss
Net income	¥1.4bn	2021-01-21 → 2022-01-20^d	Standalone	Net income loss (5-year summary)
Net income	¥899m	2020-01-21 → 2021-01-20^d	Standalone	Net income loss (5-year summary)
Net income	¥2.4bn	2019-01-21 → 2020-01-20^d	Standalone	Net income loss (5-year summary)
Total assets	¥124.8bn	at 2024-01-20	Standalone	Assets
Total assets	¥122.7bn	at 2023-01-20	Standalone	Assets
Total assets	¥122.2bn	at 2022-01-20^d	Standalone	Total assets (5-year summary)
Total assets	¥116.8bn	at 2021-01-20^d	Standalone	Total assets (5-year summary)
Total assets	¥119.1bn	at 2020-01-20^d	Standalone	Total assets (5-year summary)
Total liabilities	¥42.4bn	at 2024-01-20	Standalone	Liabilities
Total liabilities	¥42.3bn	at 2023-01-20	Standalone	Liabilities
Net assets / equity	¥82.4bn	at 2024-01-20	Standalone	Net assets
Net assets / equity	¥80.5bn	at 2023-01-20	Standalone	Net assets
Net assets / equity	¥80.1bn	at 2022-01-20^d	Standalone	Net assets
Net assets / equity	¥78.5bn	at 2021-01-20^d	Standalone	Net assets (5-year summary)
Net assets / equity	¥84.7bn	at 2020-01-20^d	Standalone	Net assets (5-year summary)
Cash and deposits	¥25.8bn	at 2024-01-20	Standalone	Cash and deposits
Cash and deposits	¥21.1bn	at 2023-01-20	Standalone	Cash and deposits
EPS (basic)	¥92.22	2023-01-21 → 2024-01-20	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥61.07	2022-01-21 → 2023-01-20	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥45.88	2021-01-21 → 2022-01-20^d	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥28.25	2020-01-21 → 2021-01-20^d	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥73.96	2019-01-21 → 2020-01-20^d	Standalone	Basic earnings loss per share (5-year summary)
Dividend per share	¥60	2023-01-21 → 2024-01-20	Standalone	Dividend paid per share (5-year summary)
Dividend per share	¥60	2022-01-21 → 2023-01-20	Standalone	Dividend paid per share (5-year summary)
Dividend per share	¥60	2021-01-21 → 2022-01-20^d	Standalone	Dividend paid per share (5-year summary)
Dividend per share	¥60	2020-01-21 → 2021-01-20^d	Standalone	Dividend paid per share (5-year summary)
Dividend per share	¥60	2019-01-21 → 2020-01-20^d	Standalone	Dividend paid per share (5-year summary)
Net assets per share	¥2,618.07	at 2024-01-20	Standalone	Net assets per share (5-year summary)
Net assets per share	¥2,564.03	at 2023-01-20	Standalone	Net assets per share (5-year summary)
Net assets per share	¥2,559.09	at 2022-01-20^d	Standalone	Net assets per share (5-year summary)
Net assets per share	¥2,512.97	at 2021-01-20^d	Standalone	Net assets per share (5-year summary)
Net assets per share	¥2,570.8	at 2020-01-20^d	Standalone	Net assets per share (5-year summary)
Equity ratio	66.0%	at 2024-01-20	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	65.6%	at 2023-01-20	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	65.6%	at 2022-01-20^d	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	67.2%	at 2021-01-20^d	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	71.1%	at 2020-01-20^d	Standalone	Equity to asset ratio (5-year summary)
ROE	3.6%	2023-01-21 → 2024-01-20	Standalone	Rate of return on equity (5-year summary)
ROE	2.4%	2022-01-21 → 2023-01-20	Standalone	Rate of return on equity (5-year summary)
ROE	1.8%	2021-01-21 → 2022-01-20^d	Standalone	Rate of return on equity (5-year summary)
ROE	1.1%	2020-01-21 → 2021-01-20^d	Standalone	Rate of return on equity (5-year summary)
ROE	2.8%	2019-01-21 → 2020-01-20^d	Standalone	Rate of return on equity (5-year summary)
Shares issued	16,568,000	at 2024-01-20	Standalone	Total number of issued shares (5-year summary)
Shares issued	16,568,000	at 2023-01-20	Standalone	Total number of issued shares (5-year summary)
Shares issued	16,568,000	at 2022-01-20^d	Standalone	Total number of issued shares (5-year summary)
Shares issued	16,568,000	at 2021-01-20^d	Standalone	Total number of issued shares (5-year summary)
Shares issued	16,568,000	at 2020-01-20^d	Standalone	Total number of issued shares (5-year summary)
Employees	39	at 2024-01-20	Standalone	Number of employees
Employees	26	at 2023-01-20	Standalone	Number of employees
Employees	23	at 2022-01-20^d	Standalone	Number of employees
Employees	19	at 2021-01-20^d	Standalone	Number of employees
Employees	21	at 2020-01-20^d	Standalone	Number of employees

Periods use the dates stated in the filing. ^d = earlier-year period dated by calendar; ^v = that date confirmed by the company's own earlier filing.

Segments · 93

Segment	Item	Period	Value
Reconciling Itemsreconciling	capex	2023-01-21 → 2024-01-20	¥926m
Reconciling Itemsreconciling	depreciation	2023-01-21 → 2024-01-20	¥793m
Reconciling Itemsreconciling	revenue	2023-01-21 → 2024-01-20	−¥366m
Reconciling Itemsreconciling	revenue intersegment	2023-01-21 → 2024-01-20	−¥366m
Reconciling Itemsreconciling	segment assets	at 2024-01-20	¥44.8bn
Reconciling Itemsreconciling	segment profit	2023-01-21 → 2024-01-20	−¥2.2bn
Domestic Beverage Businessreportable segment	capex	2023-01-21 → 2024-01-20	¥9.4bn
Domestic Beverage Businessreportable segment	depreciation	2023-01-21 → 2024-01-20	¥5.1bn
Domestic Beverage Businessreportable segment	employees	at 2024-01-20	3776 pure
Domestic Beverage Businessreportable segment	revenue	2023-01-21 → 2024-01-20	¥153.6bn
Domestic Beverage Businessreportable segment	revenue external	2023-01-21 → 2024-01-20	¥153.6bn
Domestic Beverage Businessreportable segment	revenue intersegment	2023-01-21 → 2024-01-20	¥26m
Domestic Beverage Businessreportable segment	segment assets	at 2024-01-20	¥74.7bn
Domestic Beverage Businessreportable segment	segment profit	2023-01-21 → 2024-01-20	¥4.3bn
Dy Do Pharmareportable segment	capex	2023-01-21 → 2024-01-20	¥57m
Dy Do Pharmareportable segment	depreciation	2023-01-21 → 2024-01-20	¥9m
Dy Do Pharmareportable segment	employees	at 2024-01-20	14 pure
Dy Do Pharmareportable segment	segment assets	at 2024-01-20	¥381m
Dy Do Pharmareportable segment	segment profit	2023-01-21 → 2024-01-20	−¥796m
Food Businessreportable segment	capex	2023-01-21 → 2024-01-20	¥638m
Food Businessreportable segment	depreciation	2023-01-21 → 2024-01-20	¥848m
Food Businessreportable segment	employees	at 2024-01-20	272 pure
Food Businessreportable segment	revenue	2023-01-21 → 2024-01-20	¥20.7bn
Food Businessreportable segment	revenue external	2023-01-21 → 2024-01-20	¥20.7bn
Food Businessreportable segment	revenue intersegment	2023-01-21 → 2024-01-20	¥7m
Food Businessreportable segment	segment assets	at 2024-01-20	¥21.4bn
Food Businessreportable segment	segment profit	2023-01-21 → 2024-01-20	¥993m
International Beverage Businessreportable segment	capex	2023-01-21 → 2024-01-20	¥1.2bn
International Beverage Businessreportable segment	depreciation	2023-01-21 → 2024-01-20	¥859m
International Beverage Businessreportable segment	employees	at 2024-01-20	749 pure
International Beverage Businessreportable segment	revenue	2023-01-21 → 2024-01-20	¥26.4bn
International Beverage Businessreportable segment	revenue external	2023-01-21 → 2024-01-20	¥26.4bn
International Beverage Businessreportable segment	segment assets	at 2024-01-20	¥16.7bn
International Beverage Businessreportable segment	segment profit	2023-01-21 → 2024-01-20	¥1.1bn
Pharmaceutical Related Businessreportable segment	capex	2023-01-21 → 2024-01-20	¥483m
Pharmaceutical Related Businessreportable segment	depreciation	2023-01-21 → 2024-01-20	¥1.2bn
Pharmaceutical Related Businessreportable segment	employees	at 2024-01-20	332 pure
Pharmaceutical Related Businessreportable segment	revenue	2023-01-21 → 2024-01-20	¥13.0bn
Pharmaceutical Related Businessreportable segment	revenue external	2023-01-21 → 2024-01-20	¥12.6bn
Pharmaceutical Related Businessreportable segment	revenue intersegment	2023-01-21 → 2024-01-20	¥331m
Pharmaceutical Related Businessreportable segment	segment assets	at 2024-01-20	¥19.5bn
Pharmaceutical Related Businessreportable segment	segment profit	2023-01-21 → 2024-01-20	¥367m
—segment total	capex	2023-01-21 → 2024-01-20	¥11.7bn
—segment total	depreciation	2023-01-21 → 2024-01-20	¥8.0bn
—segment total	revenue	2023-01-21 → 2024-01-20	¥213.7bn
—segment total	revenue external	2023-01-21 → 2024-01-20	¥213.4bn
—segment total	revenue intersegment	2023-01-21 → 2024-01-20	¥366m
—segment total	segment assets	at 2024-01-20	¥132.7bn
—segment total	segment profit	2023-01-21 → 2024-01-20	¥5.9bn
Reconciling Itemsreconciling	capex	2022-01-21 → 2023-01-20	¥1.5bn
Reconciling Itemsreconciling	depreciation	2022-01-21 → 2023-01-20	¥373m
Reconciling Itemsreconciling	revenue	2022-01-21 → 2023-01-20	−¥636m
Reconciling Itemsreconciling	revenue intersegment	2022-01-21 → 2023-01-20	−¥636m
Reconciling Itemsreconciling	segment assets	at 2023-01-20	¥47.8bn
Reconciling Itemsreconciling	segment profit	2022-01-21 → 2023-01-20	−¥1.6bn
Domestic Beverage Businessreportable segment	capex	2022-01-21 → 2023-01-20	¥8.3bn
Domestic Beverage Businessreportable segment	depreciation	2022-01-21 → 2023-01-20	¥4.6bn
Domestic Beverage Businessreportable segment	revenue	2022-01-21 → 2023-01-20	¥109.8bn
Domestic Beverage Businessreportable segment	revenue external	2022-01-21 → 2023-01-20	¥109.7bn
Domestic Beverage Businessreportable segment	revenue intersegment	2022-01-21 → 2023-01-20	¥25m
Domestic Beverage Businessreportable segment	segment assets	at 2023-01-20	¥60.4bn
Domestic Beverage Businessreportable segment	segment profit	2022-01-21 → 2023-01-20	¥2.8bn
Dy Do Pharmareportable segment	capex	2022-01-21 → 2023-01-20	¥1m
Dy Do Pharmareportable segment	depreciation	2022-01-21 → 2023-01-20	¥2m
Dy Do Pharmareportable segment	segment assets	at 2023-01-20	¥1.1bn
Dy Do Pharmareportable segment	segment profit	2022-01-21 → 2023-01-20	−¥499m
Food Businessreportable segment	capex	2022-01-21 → 2023-01-20	¥877m
Food Businessreportable segment	depreciation	2022-01-21 → 2023-01-20	¥848m
Food Businessreportable segment	revenue	2022-01-21 → 2023-01-20	¥19.6bn
Food Businessreportable segment	revenue external	2022-01-21 → 2023-01-20	¥19.6bn
Food Businessreportable segment	revenue intersegment	2022-01-21 → 2023-01-20	¥8m
Food Businessreportable segment	segment assets	at 2023-01-20	¥21.8bn
Food Businessreportable segment	segment profit	2022-01-21 → 2023-01-20	¥765m
International Beverage Businessreportable segment	capex	2022-01-21 → 2023-01-20	¥522m
International Beverage Businessreportable segment	depreciation	2022-01-21 → 2023-01-20	¥718m
International Beverage Businessreportable segment	revenue	2022-01-21 → 2023-01-20	¥18.9bn
International Beverage Businessreportable segment	revenue external	2022-01-21 → 2023-01-20	¥18.9bn
International Beverage Businessreportable segment	segment assets	at 2023-01-20	¥13.5bn
International Beverage Businessreportable segment	segment profit	2022-01-21 → 2023-01-20	−¥1.1bn
Pharmaceutical Related Businessreportable segment	capex	2022-01-21 → 2023-01-20	¥220m
Pharmaceutical Related Businessreportable segment	depreciation	2022-01-21 → 2023-01-20	¥1.2bn
Pharmaceutical Related Businessreportable segment	revenue	2022-01-21 → 2023-01-20	¥12.5bn
Pharmaceutical Related Businessreportable segment	revenue external	2022-01-21 → 2023-01-20	¥11.9bn
Pharmaceutical Related Businessreportable segment	revenue intersegment	2022-01-21 → 2023-01-20	¥601m
Pharmaceutical Related Businessreportable segment	segment assets	at 2023-01-20	¥19.7bn
Pharmaceutical Related Businessreportable segment	segment profit	2022-01-21 → 2023-01-20	¥347m
—segment total	capex	2022-01-21 → 2023-01-20	¥9.9bn
—segment total	depreciation	2022-01-21 → 2023-01-20	¥7.4bn
—segment total	revenue	2022-01-21 → 2023-01-20	¥160.8bn
—segment total	revenue external	2022-01-21 → 2023-01-20	¥160.1bn
—segment total	revenue intersegment	2022-01-21 → 2023-01-20	¥636m
—segment total	segment assets	at 2023-01-20	¥116.4bn
—segment total	segment profit	2022-01-21 → 2023-01-20	¥2.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,755

Item	Context	Value	Unit
Total shareholder return	Prior4YearInstant_NonConsolidatedMember	0.810
Total shareholder return	Prior3YearInstant_NonConsolidatedMember	0.954
Total shareholder return	Prior2YearInstant_NonConsolidatedMember	0.871
Total shareholder return	Prior1YearInstant_NonConsolidatedMember	0.893
Total shareholder return	CurrentYearInstant_NonConsolidatedMember	1.131
Total return on share price index	Prior4YearInstant_NonConsolidatedMember	1.148
Total return on share price index	Prior3YearInstant_NonConsolidatedMember	1.247
Total return on share price index	Prior2YearInstant_NonConsolidatedMember	1.335
Total return on share price index	Prior1YearInstant_NonConsolidatedMember	1.363
Total return on share price index	CurrentYearInstant_NonConsolidatedMember	1.820
Number of employees	CurrentYearInstant_jpcrp030000-asr_E00424-000DomesticBeverageBusinessReportableSegmentsMember	3776
Average number of temporary workers	CurrentYearInstant_jpcrp030000-asr_E00424-000DomesticBeverageBusinessReportableSegmentsMember	68
Number of employees	CurrentYearInstant_jpcrp030000-asr_E00424-000InternationalBeverageBusinessReportableSegmentsMember	749
Average number of temporary workers	CurrentYearInstant_jpcrp030000-asr_E00424-000InternationalBeverageBusinessReportableSegmentsMember	－
Number of employees	CurrentYearInstant_jpcrp030000-asr_E00424-000PharmaceuticalRelatedBusinessReportableSegmentsMember	332
Average number of temporary workers	CurrentYearInstant_jpcrp030000-asr_E00424-000PharmaceuticalRelatedBusinessReportableSegmentsMember	13
Number of employees	CurrentYearInstant_jpcrp030000-asr_E00424-000FoodBusinessReportableSegmentsMember	272
Average number of temporary workers	CurrentYearInstant_jpcrp030000-asr_E00424-000FoodBusinessReportableSegmentsMember	255
Number of employees	CurrentYearInstant_jpcrp030000-asr_E00424-000DyDoPharmaReportableSegmentsMember	14
Average number of temporary workers	CurrentYearInstant_jpcrp030000-asr_E00424-000DyDoPharmaReportableSegmentsMember	－
Number of employees	CurrentYearInstant_CorporateSharedMember	39
Average number of temporary workers	CurrentYearInstant_CorporateSharedMember	－
Number of employees	CurrentYearInstant	5182
Average number of temporary workers	CurrentYearInstant	336
Number of employees	CurrentYearInstant_NonConsolidatedMember	39
Average age years information about reporting company information about employees	CurrentYearInstant_NonConsolidatedMember	39.1
Average length of service years information about reporting company information about employees	CurrentYearInstant_NonConsolidatedMember	10.1
Average annual salary information about reporting company information about employees	CurrentYearInstant_NonConsolidatedMember	7358031	JPY
Number of employees	CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember	39
Number of employees	CurrentYearInstant_NonConsolidatedMember	39
Research and development expenses research and development activities	CurrentYearDuration	1485000000	JPY
Research and development expenses research and development activities	CurrentYearDuration_jpcrp030000-asr_E00424-000DomesticBeverageBusinessReportableSegmentsMember	454000000	JPY
Research and development expenses research and development activities	CurrentYearDuration_jpcrp030000-asr_E00424-000InternationalBeverageBusinessReportableSegmentsMember	25000000	JPY
Research and development expenses research and development activities	CurrentYearDuration_jpcrp030000-asr_E00424-000PharmaceuticalRelatedBusinessReportableSegmentsMember	256000000	JPY
Research and development expenses research and development activities	CurrentYearDuration_jpcrp030000-asr_E00424-000FoodBusinessReportableSegmentsMember	144000000	JPY
Research and development expenses research and development activities	CurrentYearDuration_jpcrp030000-asr_E00424-000DyDoPharmaReportableSegmentsMember	603000000	JPY
Capital expenditures overview of capital expenditures etc	CurrentYearDuration	11593000000	JPY
Capital expenditures overview of capital expenditures etc	CurrentYearDuration_jpcrp030000-asr_E00424-000DomesticBeverageBusinessReportableSegmentsMember	8313000000	JPY
Capital expenditures overview of capital expenditures etc	CurrentYearDuration_jpcrp030000-asr_E00424-000InternationalBeverageBusinessReportableSegmentsMember	1175000000	JPY
Capital expenditures overview of capital expenditures etc	CurrentYearDuration_jpcrp030000-asr_E00424-000PharmaceuticalRelatedBusinessReportableSegmentsMember	483000000	JPY
Capital expenditures overview of capital expenditures etc	CurrentYearDuration_jpcrp030000-asr_E00424-000FoodBusinessReportableSegmentsMember	637000000	JPY
Capital expenditures overview of capital expenditures etc	CurrentYearDuration_jpcrp030000-asr_E00424-000DyDoPharmaReportableSegmentsMember	57000000	JPY
Number of issued shares as of fiscal year end issued shares total number of shares etc	FilingDateInstant_OrdinaryShareMember	16568500
Number of issued shares as of filing date issued shares total number of shares etc	FilingDateInstant_OrdinaryShareMember	33137000
Number of issued shares as of fiscal year end issued shares total number of shares etc	FilingDateInstant	16568500
Number of issued shares as of filing date issued shares total number of shares etc	FilingDateInstant	33137000
Number of shares constituting one unit	CurrentYearInstant_OrdinaryShareMember	100
Number of shareholders national and local governments	CurrentYearInstant_OrdinaryShareMember	－
Number of shareholders financial institutions	CurrentYearInstant_OrdinaryShareMember	15
Number of shareholders financial service providers	CurrentYearInstant_OrdinaryShareMember	17

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed

balance sheet identity	consolidated 2023-01-20	pass
balance sheet identity	consolidated 2024-01-20	pass rounding
balance sheet identity	non_consolidated 2023-01-20	pass
balance sheet identity	non_consolidated 2024-01-20	pass rounding
dei present		pass
period resolution		pass
statement vs summary · net assets	consolidated 2022-01-20	pass
statement vs summary · net assets	consolidated 2023-01-20	pass
statement vs summary · net assets	consolidated 2024-01-20	pass
statement vs summary · net assets	non_consolidated 2022-01-20	pass
statement vs summary · net assets	non_consolidated 2023-01-20	pass
statement vs summary · net assets	non_consolidated 2024-01-20	pass
statement vs summary · net income attributable to parent	consolidated 2022-01-21/2023-01-20	pass
statement vs summary · net income attributable to parent	consolidated 2023-01-21/2024-01-20	pass
statement vs summary · operating cash flow	consolidated 2022-01-21/2023-01-20	pass
statement vs summary · operating cash flow	consolidated 2023-01-21/2024-01-20	pass
statement vs summary · revenue	consolidated 2022-01-21/2023-01-20	pass
statement vs summary · revenue	consolidated 2023-01-21/2024-01-20	pass
statement vs summary · revenue	non_consolidated 2022-01-21/2023-01-20	pass
statement vs summary · revenue	non_consolidated 2023-01-21/2024-01-20	pass
statement vs summary · total assets	consolidated 2023-01-20	pass
statement vs summary · total assets	consolidated 2024-01-20	pass
statement vs summary · total assets	non_consolidated 2023-01-20	pass
statement vs summary · total assets	non_consolidated 2024-01-20	pass